Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867445 | 0.90 | HPGD (0.51) | TSHRSMN1; SMN2HPGDDRD2DRD3 | |
| SCHEMBL14181486 | 0.90 | HPGD (0.51) | TSHRSMN1; SMN2HPGDDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL4836766 | 0.89 | HPGD (0.50) | TSHRSMN1; SMN2HPGDDRD2DRD3 | |
| SCHEMBL4837020 | 0.88 | HPGD (0.51) | TSHRSMN1; SMN2HPGDDRD2DRD3 | |
| SCHEMBL4834333 | 0.88 | DRD3 (0.49) | TSHRSMN1; SMN2HPGDDRD2DRD3 | |
| SCHEMBL4828355 | 0.88 | HPGD (0.50) | TSHRSMN1; SMN2HPGDDRD2DRD3 | |
| SCHEMBL4828371 | 0.86 | TSHR (0.53) | TSHRSMN1; SMN2HPGDDRD2DRD3 | |
| SCHEMBL4834840 | 0.84 | TSHR (0.57) | TSHRSMN1; SMN2HPGDDRD2DRD3 | |
| SCHEMBL4838110 | 0.84 | SMN1; SMN2 (0.49) | TSHRSMN1; SMN2HPGDDRD2DRD3 | |
| SCHEMBL4839715 | 0.82 | SMN1; SMN2 (0.49) | TSHRSMN1; SMN2HPGDDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368476-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| WO-2005097770-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | AXYS PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | HDAC1, HDAC5, HDAC10 | TSHR 3505/4885SMN1; SMN2 2607/4885HPGD 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.